The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 3.9% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is momentum reading oversold. Over the past year the shares are down 21%. Our forward projection puts the odds of a 10% gain over the next month near 17%. The street (12 analysts) rates it strong buy, with a mean price target of $8812.
Indofood Sukses Makmur
INDF.JK · IDX · IDR · Market cap $56.41T · 98,075 employees
PT Indofood Sukses Makmur Tbk operates as a food solutions company in Indonesia, rest of Asia, Africa, and internationally.
FAIL · Does not pass the screenPrice as of 5 Nov 2026Daily close, not a live quote
Screened 2026-11-05 · the tape above runs as of 18:01 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
- Price6,725.00 IDR at the 5 Nov 2026 close
- Our value readUndervalued vs our fair value, as of 5 Nov 2026
- Our regime readDistribution, as of 5 Nov 2026
- Ethical screenDoes not pass
- Last reviewed5 Nov 2026 (1 days ago)
- Release timesRelease and earnings times on your chart: Event Guard Mentor
A summary of the dated readings below, not a live quote and not advice.
Our fair-value range: 10,906.25 IDR to 13,100.00 IDR, base estimate 10,906.25 IDR (screen dated 2026-11-05).
- Trend Distribution
- Insiders no filings inside 60 days, left as found
- Positioning no disclosures inside 60 days, left as found
- Options no verdict drawn today, left as found
- Ethical does not pass the values gate
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
This name holds its distribution label.
Indofood Sukses Makmur holds its Distribution at $6,725.00. Elevated stress, defensive posture warranted, held for 9 days.
| Phase | Distribution · caution |
| Quantitative state | Elevated stress, defensive posture warranted, held for 9 days |
| Price at the screen | $6,725.00 |
| Valuation | 5.63 trailing · 5.38 forward price to earnings |
| Values screen | FAIL · score 70.0 |
| Beta | 0.05 |
Five Screens, Shown in Full
Does not pass. Debt ratio
| Test | Figure | Limit | What it means | Status |
|---|---|---|---|---|
| Business activity | Permissible | Core business clean | Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending. | Pass |
| Debt load | 34.39% | Below 33% | Interest-bearing debt is 34.4% of its assets, above the one-third ceiling the screen allows. | Fail |
| Interest-bearing cash | 2.30% | Below 33% | Cash held in interest-bearing accounts and securities is 2.3% of assets, under the one-third limit. | Pass |
| Receivables | 26.64% | Below 49% | Money owed to the company is 26.6% of assets, under the 49% limit. | Pass |
| Revenue purity | 1.35% | Below 5% | Only 1.3% of revenue comes from non-compliant sources, under the 5% line. | Pass |
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical ReadWhy It Falls Short, in Plain English
Indofood Sukses Makmur's business is in a permissible area, but its interest-bearing debt is about 34% of the company, just over the ~33% line, so it does not pass on the financial screens.
Read as at 2026-11-05. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when INDF.JK's ethical verdict changes
Today INDF.JK does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
The Fair Value Range
Our analysis reads Undervalued vs our fair value, as of 5 Nov 2026: it trades at roughly a 40% discount to our 10,906.25 IDR fair value, 7.40% revenue growth.
How a fair value is estimated: discounted cash flow (DCF).
Fair value range in IDR, drawn from the 2026-11-05 screen. The gold marker is the market price at the same screen. A 38.3% discount to the base estimate.
Third-party analyst targets: 12 covering, consensus Strong Buy. The average target sits +30% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & ProjectionsWhere our models see it going: fair-value estimate 10,906.25 IDR, with a range of 10,906.25 IDR to 13,100.00 IDR, dated to the 2026-11-05 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain WordsWhy it stands out
A 7%-growth business trading at just 5.4x forward earnings. That is a 40% discount to our 10,906.25 IDR fair value: the market is pricing it cautiously while the fundamentals argue otherwise. 12 analysts rate it Strong Buy with a 8,725.00 IDR average target, about 30% above the screened price.
| Forward P/E | 5.4xcheap for a company growing this fast |
| Trailing P/E | 5.6xvery cheap relative to earnings |
| EPS, trailing | 1,243.88 |
| EPS, forward | 1,300.01 |
| Revenue growth | +7.4%slow but positive growth |
| Profit margin | 8.7%thin but positive margins |
| Return on equity | 13.3%a solid return on shareholder capital |
| Dividend yield | 436.00% |
| Debt to equity | 0.61moderate, manageable leverage |
| Beta | 0.05barely tracks the market's swings |
| 52-week range | 5,850.00 - 8,825.00 |
| Market cap | $56.41T |
| Employees | 98,075 |
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The things to watch: its business and earnings are exposed to Indonesia and to currency swings.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to TradeINDF.JK trades on IDX (the company is based in Indonesia). As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
Every Entry, As Written
The framework has shifted from markdown to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is momentum reading oversold. Over the past year the shares are down 21%. Our forward projection puts the odds of a 10% gain over the next month near 17%. The street (12 analysts) rates it strong buy, with a mean price target of $8812.
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is momentum reading bearish. Over the past year the shares are down 21%. Our forward projection puts the odds of a 10% gain over the next month near 17%. The street (12 analysts) rates it strong buy, with a mean price target of $8812.
The framework has shifted from accumulation to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 8.9% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 21%. Our forward projection puts the odds of a 10% gain over the next month near 17%. The street (12 analysts) rates it strong buy, with a mean price target of $8812.
The framework has shifted from markdown to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 21%. Our forward projection puts the odds of a 10% gain over the next month near 17%. The street (12 analysts) rates it strong buy, with a mean price target of $8812.
Our analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 21%. Our forward projection puts the odds of a 10% gain over the next month near 17%. The street (12 analysts) rates it strong buy, with a mean price target of $8812. It reported earnings in this window, a natural checkpoint for the thesis.
Our analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 21%. Our forward projection puts the odds of a 10% gain over the next month near 17%. The street (12 analysts) rates it strong buy, with a mean price target of $8812. It reported earnings in this window, a natural checkpoint for the thesis.
Our analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 21%. Our forward projection puts the odds of a 10% gain over the next month near 17%. The street (12 analysts) rates it strong buy, with a mean price target of $8812. It reported earnings in this window, a natural checkpoint for the thesis.
Our analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 21%. Our forward projection puts the odds of a 10% gain over the next month near 17%. The street (12 analysts) rates it strong buy, with a mean price target of $8812. It reported earnings in this window, a natural checkpoint for the thesis.
The framework has shifted from accumulation to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 21%. Our forward projection puts the odds of a 10% gain over the next month near 17%. The street (12 analysts) rates it strong buy, with a mean price target of $8812. It reported earnings in this window, a natural checkpoint for the thesis.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $6,925.00 | -9.8% | · | $903 | -9.8% |
| 2 months | $6,700.00 | -6.7% | · | $933 | -6.7% |
| 3 months | $6,050.00 | +3.3% | · | $1,033 | +3.3% |
| 6 months | $6,775.00 | -7.8% | · | $923 | -7.8% |
| 1 year | $7,920.00 | -21.1% | $280.00 | $824 | -17.6% |
| 2 years | $5,707.30 | +9.5% | $547.00 | $1,191 | +19.1% |
| 3 years | $6,625.89 | -5.7% | $804.00 | $1,065 | +6.5% |
| 5 years | $5,143.32 | +21.5% | $1,360.00 | $1,480 | +48.0% |
Historical returns from market close data. Past performance does not guarantee future results.
This entry now belongs to the ledger. Whatever INDF.JK does next, these words stay.
Thirteen thousand names carry this page. One desk keeps them honest.
Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.
Join the deskScreening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.